A Single Arm,Multi-center,Phase II Clinical Trial of Combined Therapy for Orelabrutinib,Rituximab and Methotrexate(RMO)in Newly-diagnosed Primary Center Nervous System Lymphoma(PCNSL)
Latest Information Update: 12 Feb 2025
At a glance
- Drugs Methotrexate (Primary) ; Orelabrutinib (Primary) ; Rituximab (Primary)
- Indications CNS cancer; Diffuse large B cell lymphoma
- Focus Therapeutic Use
Most Recent Events
- 09 Dec 2024 According to an InnoCare Pharma Media Release, preliminary efficacy data from this study were presented at the ongoing 66th American Society of Hematology (ASH) Annual Meeting.
- 09 Dec 2024 Results presented in the InnoCare Pharma Media Release.
- 27 Sep 2022 New trial record